New Antiarrhythmic drugs in pediatric use: Amiodarone

T. Paul, P. Guccione

Research output: Contribution to journalArticle


Amiodarone, a class III antiarrhythmic agent, prolongs action potential duration and refractoriness of all cardiac structures. The drug is more rapidly metabolized in pediatric patients than in adults, but its kinetics are still unique compared with other drugs. Due to the unusual pharmacokinetic characteristics of amiodarone, treatment has to be started by administering loading doses, and there is a significant delay both in the achievement of the full antiarrhythmic effect and in the development of side effects. Amoidarone is a highly effective agent in pediatric patients with automatic and reentrant supraventricular tachycardia as well as in refractory atrial flutter. Efficacy in ventricular tachycardia has been shown to be variable depending on the underlying anatomical substrate. The incidence of side effects is lower than that observed in adult studies with similar duration of therapy but their incidence is still significant. Amiodarone treatment is associated with a significant risk of proarrhythmic effects, requiring hospitalization of the patient during the loading period.

Original languageEnglish
Pages (from-to)132-138
Number of pages7
JournalPediatric Cardiology
Issue number3
Publication statusPublished - May 1994


  • Amiodarone
  • Electrophysiology
  • Hemodynamics
  • Pharmacokinetics
  • Proarrhythmia
  • Systemic side effects

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'New Antiarrhythmic drugs in pediatric use: Amiodarone'. Together they form a unique fingerprint.

  • Cite this